These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12144543)

  • 21. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma.
    Vivas S; Ruiz de Morales JM; Ramos F; Suárez-Vilela D
    N Engl J Med; 2006 Jun; 354(23):2514-5. PubMed ID: 16760460
    [No Abstract]   [Full Text] [Related]  

  • 22. Remission of adult acute lymphocytic leukaemia with alemtuzumab.
    Laporte JP; Isnard F; Garderet L; Fouillard L; Gorin NC
    Leukemia; 2004 Sep; 18(9):1557-8. PubMed ID: 15229619
    [No Abstract]   [Full Text] [Related]  

  • 23. Alemtuzumab in T-cell lymphoproliferative disorders.
    Dearden CE; Matutes E
    Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab in peripheral T-cell malignancies.
    Dearden C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

  • 27. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of alemtuzumab in the management of T-cell malignancies.
    Dearden C
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibody-based therapy of lymphoid neoplasms: what's on the horizon?
    Davis AT
    Semin Hematol; 2000 Oct; 37(4 Suppl 7):34-42. PubMed ID: 11147488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated molluscum contagiosum in a patient with chronic lymphocytic leukaemia after alemtuzumab.
    Pitini V; Arrigo C; Barresi G
    Br J Haematol; 2003 Nov; 123(4):565. PubMed ID: 14616955
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
    Wulf GG; Hasenkamp J; Jung W; Chapuy B; Truemper L; Glass B
    Bone Marrow Transplant; 2005 Aug; 36(3):271-3. PubMed ID: 15937499
    [No Abstract]   [Full Text] [Related]  

  • 32. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
    Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
    Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
    [No Abstract]   [Full Text] [Related]  

  • 33. Alemtuzumab.
    Weaver TA; Kirk AD
    Transplantation; 2007 Dec; 84(12):1545-7. PubMed ID: 18165760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful use of alemtuzumab in a child with refractory peripheral T-cell posttransplant lymphoproliferative disorder.
    Bartakke S; Abla O; Weitzman S
    J Pediatr Hematol Oncol; 2008 Oct; 30(10):787-8. PubMed ID: 19011483
    [No Abstract]   [Full Text] [Related]  

  • 35. Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab.
    Chan HE; Jilani I; Chang R; Albitar M
    Methods Mol Biol; 2007; 378():159-65. PubMed ID: 18605084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT; Petruska PJ
    Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
    [No Abstract]   [Full Text] [Related]  

  • 37. Comment on alemtuzumab and inclusion body myositis.
    Greenberg SA
    Brain; 2010 May; 133(Pt 5):e135; author reply e136. PubMed ID: 19892769
    [No Abstract]   [Full Text] [Related]  

  • 38. Alemtuzumab in kidney-transplant recipients.
    Luan FL
    N Engl J Med; 2011 Aug; 365(7):671; author reply 671-2. PubMed ID: 21848469
    [No Abstract]   [Full Text] [Related]  

  • 39. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.
    Chu D; Stevens M; Gladstone DE
    Rheumatol Int; 2007 Oct; 27(12):1173-5. PubMed ID: 17443327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.